A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.
The firm's Q3 2024 revenues rose 33 percent year over year as both its genomics and data and services revenues increased in the double-digit percent range.
As the company explores new testing areas and technologies, the prostate cancer prognostic has become an important backbone.
China Instrument Sales Drag on Revvity Life Science Segment as Company Q3 Revenues Rise 2 Percent
Premium
Similar to other firms, the firm said that it has been negatively impacted as customers in China wait for government stimulus funding to arrive.
Next Implementation Steps Unclear After EU Parliament Votes to Support IVD Regulation Review
Premium
The parliamentary resolution drew the immediate support of MedTech Europe and VDGH, but it remains unclear what the immediate outcome of the resolution will be.